GSK Consent Decree Sets “Aggressive” 150-Day Timeline For GMP Conformity
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline's consent decree mandates that the company notify the agency within 150 days of the corrective measures it has taken or plans to take in addressing FDA's good manufacturing practice concerns
You may also be interested in...
GSK Consent Decree Includes $650 Mil. Bond, Third-Party Inspections
GlaxoSmithKline appears to have negotiated a more favorable consent decree agreement with FDA compared to previous pharmaceutical companies facing similar action
FDA Seizure Of GSK Products Exemplifies Heightened Warning Letter Gravitas
The seizure of two of GlaxoSmithKline's major prescription drugs is an example of the increased seriousness FDA is placing on individual warning letters
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC